ERBB2 and neoplasm: Kijanka et al. (2013) conjugated an anti-HER-2 Nb (11A4) to IRDye800CW and demonstrated that 11A4-IRDye800CW increased tumor accumulation and tumor-to-background ratios as compared to trastuzumab-IRDye800CW in human xenograft breast cancer models (Table 2) [42].